Novartis new data show Cosentyx® improved quality of life over 5 years
Novartis announced additional results from the SCULPTURE study showing that two thirds of moderate to severe plaque psoriasis patients treated with Cosentyx® (secukinumab) reported no impact of skin disease on their quality of life through 5 years. February 16, 2018